Clinical response to treatment (N = 72)
| . | No. of patients . | % (95% CI) . | Average time to response, d (range) . |
|---|---|---|---|
| Response* | |||
| Complete response | 28 | 38.89 (28.2-50.5) | 266.7 (62-640) |
| Near-complete response | 10 | 13.89 (7.3-23.4) | 155.3 (30-563) |
| Very good partial response | 15 | 20.83 (12.6-31.3) | 158 (28- 786) |
| Partial response | 12 | 16.67 (9.4-26.6) | 44.4 (27-255) |
| Minor response | 4 | 5.56. (1.8-12.9) | — |
| Stable disease | 0 | 4.17 (1.1- 10.9) | — |
| Overall response | 65 | 90.3 (81.7- 95.6) | — |
| Total, intent-to-treat | 72 | 100 | — |
| Response* with New UnifiedResponse Criteria | |||
| Stringent complete response | 22 | 30.6 (20.8- 41.9) | 266.7 (62- 640) |
| Complete response | 6 | 8.3 (3.4- 16.5) | 155.3 (30-563) |
| Very good partial response | 25 | 34.72 (24.4- 46.2) | 158 (28-786) |
| Partial response | 12 | 16.7 (9.4-26.6) | 44.4 (27-255) |
| Minor response | 4 | 5.6 (1.8-12.9) | — |
| Stable disease | 0 | 0 | — |
| Nonevaluable patients | 3 | 4.17 (1.1- 10.9) | — |
| Overall response | 65 | 90.3 (81.7- 95.6) | — |
| Total, intent-to-treat | 72 | 100 | — |
| . | No. of patients . | % (95% CI) . | Average time to response, d (range) . |
|---|---|---|---|
| Response* | |||
| Complete response | 28 | 38.89 (28.2-50.5) | 266.7 (62-640) |
| Near-complete response | 10 | 13.89 (7.3-23.4) | 155.3 (30-563) |
| Very good partial response | 15 | 20.83 (12.6-31.3) | 158 (28- 786) |
| Partial response | 12 | 16.67 (9.4-26.6) | 44.4 (27-255) |
| Minor response | 4 | 5.56. (1.8-12.9) | — |
| Stable disease | 0 | 4.17 (1.1- 10.9) | — |
| Overall response | 65 | 90.3 (81.7- 95.6) | — |
| Total, intent-to-treat | 72 | 100 | — |
| Response* with New UnifiedResponse Criteria | |||
| Stringent complete response | 22 | 30.6 (20.8- 41.9) | 266.7 (62- 640) |
| Complete response | 6 | 8.3 (3.4- 16.5) | 155.3 (30-563) |
| Very good partial response | 25 | 34.72 (24.4- 46.2) | 158 (28-786) |
| Partial response | 12 | 16.7 (9.4-26.6) | 44.4 (27-255) |
| Minor response | 4 | 5.6 (1.8-12.9) | — |
| Stable disease | 0 | 0 | — |
| Nonevaluable patients | 3 | 4.17 (1.1- 10.9) | — |
| Overall response | 65 | 90.3 (81.7- 95.6) | — |
| Total, intent-to-treat | 72 | 100 | — |
— indicates not measured.
Sustained for at least 6 weeks.